4th ENOVA ADJUVANT WORKSHOP, 20-22 September 2021, Genova, ITALY

This workshop was planned for 23-25 March 2020, but due to COVID-19 pandemic have been moved to a hybrid (online-physical) at the same place but new time point: 20-22 september 2021.

 

The next ENOVA workshop will held in Genova, ITALY. Beside the administrative meetings, such as MC meeting or networking activity, there will be one keynote presentation (Vaccine-controlled infective diseases and cancer burden: achievements and perspectives, Prof. Alberto Izzotti, Genova University) and five scientific sessions (Improving existing adjuvant-based formulations; Novel vaccine adjuvants; Scale-up procedures for adjuvant production; Assays for the characterization of antigen-adjuvant formulations, and Selecting protocols for preclinical testing and down selection).

Meeting report

The procedure for registration of the meeting is:

  1. before August 28th you sign up for participation via the doodle link: https://doodle.com/poll/kxkkcqb2su9mkdmf. There is an upper limit of 60 participants, so do not hesitate.
  2. Hereafter you will receive an official COST invite, where you register your participation.
  3. At the same time (deadline August 28th), you submit a title for a lightning talk (10-15 minutes), where you suggest a focus are among the five listed above. Also write 3-4 lines about the topic of your talk. Send to me (den@ssi.dk). There will be a maximum of 30 talks (prioritized by submission sequence)
  4. Early September, you will receive a first draft of the detailed program.

Agenda Monday September 20th 2021

 

13:30 – 13:40   Welcome to Genova, Camillo Rosano (IRCCS Policlinico San Martino - Genova, Italy) & Giacomo Drago (CEO of GIAMpharma Int).

 

13:40 – 13:45   Introduction to ENOVA & the 4th Adjuvant Workshop, Dennis Christensen (SSI, DK)

13:45 – 14:15   Keynote: Vaccine-controlled infective diseases and cancer burden: achievements and perspectives Proff. Alberto Izzotti, (Genova University, Italy)

14:15 – 15:30   Session 1:       Improving existing adjuvant-based formulations

  • To evaluate whether mucosal adjuvants enhance the immunological responses of pigs immunized with Nipah Virus F and G protein replication incompetent paramyxovirus vectored vaccines, Louise Cosby (Agri-Food and Biosciences Institute, Belfast, UK) online
  • Using microcontainers for oral delivery of vaccines, Philip Hassing Ronøe Carlsen (PhD student DTU, Denmark) Genova
  • The adjuvant LT-K63 enhances B cell activation and survival factors expression in neonatal mice - comparative study of LT-K63 and other adjuvants on the induction of germinal center and ASC, Stefania P. Bjarnarson (University of Iceland/National University Hospital of Iceland) online
  • Discussion

 

15:30 – 16:00   Coffee break

 

16:00 – 17:30   Session 2:       Novel vaccine adjuvants

  • Development of new adjuvants / adjuvant formulations based on purified Astragalus saponin, Astragaloside VII (AST VII), Nilgün Yakuboğullari (İzmir Institute of Technology, Turkey) online
  • Protein corona and rigidity affect regulatory T-cells induction using liposomes, Bram Slütter (LUMC, NL), online
  • Thermogelling and mucoadhesive hydrogels as sublingual boosters for obtaining mucosal immunity"., Lorena Garcia del Rio, (STSM, PhD student, University Santiago de Compostella, Spain) Genova
  • In vitro investigations of adjuvant properties of selected novel PRR agonists, Samo Guzelj (University of Ljubljana, Slovenia) online
  • The IC-tagging multipurpose platform, Tomas Boirazian (NIBSC, UK) online/Genova
  • Discussion

 

Evening on your own 

 

Agenda Tuesday September 21st 2021

 

08:30 – 10:00   Session 3:       Assays for the characterization of antigen-adjuvant formulations

  • Comparison of different assay formats for characterisation of adjuvant activity, Sandra Diebold (NIBSC, UK) online
  • Ex-vivo assessment by Comet assay of Allostatine, Imène Ben Toumia (Faculty of Pharmacy of Monastir, Tunesia) Genova
  • Investigating the role of antigen-adjuvant interaction, Katharina Wørzner (PhD Student, SSI, Denmark) Genova
  • Optimisation of a vaccine against Melioidosis, Siobhán McClean (University College Dublin, Ireland) online
  • Discussion

 

10:00 – 10:30   Coffee break

 

10:30 – 13:00   MC meeting (only for members of the Management Committee)

 

13:00 – 14:00   Lunch

 

14:00 – 15:30   Session 4:       Selecting protocols for preclinical testing and down selection

  • Vaccine Adjuvants Differentially Affect Kinetics of Antibody and Germinal Center Responses, thus Confounding Adjuvant Comparisons, Dennis Christensen (SSI, Denmark) Genova
  • Chitin derived polymers as vaccine adjuvants, Ed Lavelle.(Trinity College Dublin, Ireland)  Genova
  • Discussion

 

15:30 – 16:00   Coffee break (group photo)

 

16:00 – 17:00   Session 5:       Scale-up procedures for adjuvant production

  • Preparation of liposomal vaccine adjuvants with hydrodynamic flow-focusing microfluidics, Tandrup Schmidt, (SSI, Denmark) online
  • Modelling a pandemic INFLUENZA vaccine manufacturing using CrisBio® technology, Ana Falcon (Algenex, Spain) online
  • Discussion

20:00               Gala Dinner at the Ristorante "I tre merli"

Agenda Wednesday September 22nd 2020

09:00 – 09:30               Summary of MC meeting discussion

 

9:30 – 10:00                 Dennis Christensen – funding opportunities for further network activities- participants who will join online/Genova are encouraged to interact in this session and give suggestions about funding opportunities.

 

10:10 – 12:00               Network discussions

  • Introduction of COST virtual networking tools (Brankica Filipic)
  • Activities of Grant Period 5 (6 month extension period)
    • Planning of 5th Adjuvant Workshop (Israel) (Uri Marchaim and Jacob Pitcovski)
    • Outline of joint ENOVA manuscript(s)- (Maria Lawrenz)
  • Preparation of ENOVA Final Assessment Report (Maria Lawrenz)
  • Continuation of ENOVA network (Maria Lawrenz and Dennis Christensen)

 

12:00                           End of meeting

Published Feb. 28, 2020 11:27 PM - Last modified Nov. 5, 2021 3:53 PM